Concepedia

Paul Delmar

PD

46

Publications

3.2K

Citations

26

H-Index

2004

Active since

Affiliations

Roche (Switzerland)(Current)

Roche (United Kingdom)

Washington University in St. Louis

University College London

University of Alabama at Birmingham

Paul Delmar is an author at Roche (Switzerland) specializing in medicine, pathology, and oncology.

ORCID

Top concepts

Publications per year

2004–2025

46

Publications

46

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

Eric Van Cutsem, Sanne de Haas, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2012 · 482 citations

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Stephen Salloway, Martin R. Farlow, Eric McDade et al. · Nature Medicine · 2021 · 349 citations · Full text

, , +9

Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease

Randall J. Bateman, Janice Smith, Michael Donohue et al. · New England Journal of Medicine · 2023 · 239 citations · Full text

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Gregory Klein, Paul Delmar, Nicola Voyle et al. · Alzheimer s Research & Therapy · 2019 · 200 citations · Full text

Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab

Bart Claes, Paul Delmar, Betül T. Yesilyurt et al. · ePrints Soton (University of Southampton) · 2012 · 189 citations · Full text

Rows per page

1–5 of 46